Related Experiment Video
Updated: May 31, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
[Non Hodgkin's lymphomas: a major breakthrough with immunotherapy]
R Firescu1, K Muylle, M Roelandts
1Services d'Hematologie clinique, Institut J. Bordet, Bruxelles.
Revue Medicale De Bruxelles
|June 22, 2011
Summary
Recent advances in immunotherapy have significantly improved outcomes for non-Hodgkin's lymphomas. New classifications aid in identifying specific lymphomas and comparing patient populations in clinical studies.
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Non-Hodgkin's lymphomas (NHL) are hematological malignancies.
- Significant therapeutic progress has been achieved in the last decade, primarily through immunotherapy.
- The incidence of NHL is increasing, linked to an aging population and other factors requiring further investigation.
Purpose:
- To provide an overview of the latest therapeutic advancements in non-Hodgkin's lymphomas.
- To highlight the role of immunotherapy, including radio-immunotherapy, in NHL treatment.
- To discuss the impact of the new WHO classification on lymphoma identification and clinical study comparisons.
Summary:
- Immunotherapy has revolutionized non-Hodgkin's lymphoma treatment over the past ten years.
- The updated WHO classification improves lymphoma identification and facilitates homogeneous population comparisons.
- Therapeutic strategies now focus on radio-immunotherapy and hematopoietic stem cell transplantation.
Impact:
- Improved patient outcomes and treatment efficacy for non-Hodgkin's lymphomas.
- Enhanced ability to conduct and compare clinical studies due to refined lymphoma classification.
- Established new therapeutic avenues, including radio-immunotherapy and stem cell transplantation, for managing NHL.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...